With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.300543-56-0,(R)-1-((4-Chlorophenyl)(phenyl)methyl)piperazine,as a common compound, the synthetic route is as follows.
General procedure: The title compound was prepared according to General Protocol B. NMR (400 MHz, DMSO-c delta 7.48 – 7.14 (m, 9H), 4.29 (s, 1 H), 2.38 (s, 4H), 2.34 – 2.20 (m, 6H); LCMS ti (Method 1) = 4.630 min, m/z 317.2 [M+H+].General Protocol B. A solution of amine (0.105 mmol) in MeOH (1.00 mL) was treated at room temperature with aldehyde (0.525 mmol to 1.05 mmol, 5.0 to 10.0 equiv.), NaCNBH4 (19.7 mg, 0.315 mmol, 3.0 equiv.) and acetic acid (0.018 mL, 0.315 mmol, 3.0 mmol). The reaction mixture was stirred at room temperature for 1 – 8 h and quenched with 1 N NaOH solution. The mixture was dried by blowing air, re-dissolved in DMSO, filtered and purified by HPLC. The title compound was prepared according to General Protocol B as a TFA salt. LCMS t, (Method 1) = 3.990 min, m/z 445.2 [M+H+]., 300543-56-0
As the paragraph descriping shows that 300543-56-0 is playing an increasingly important role.
Reference：
Patent; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; LIANG, Tsanyang Jake; FERRER, Marc; HE, Shanshan; HU, Xin; HU, Zongyi; MARUGAN, Juan Jose; SOUTHALL, Noel Terrence; XIAO, Jingbo; ZHENG, Wei; WO2015/80949; (2015); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics